Revvity Launches CE-IVDR T1D Early Detection Solution
WALTHAM, Mass. — September 24, 2026 Revvity, Inc. announced the launch of the GSP® T1D 3plex kit, a fully...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
WALTHAM, Mass. — September 24, 2026 Revvity, Inc. announced the launch of the GSP® T1D 3plex kit, a fully...
February 25, 2026 – Washington, D.C., USA New nationwide screening data from the American Red Cross shows that 1...
